(HCAT) Health Catalyst - Ratings and Ratios

Health Catalyst Inc (HCAT) is a healthcare technology company that empowers healthcare organizations to optimize their data and analytics capabilities, driving improved clinical, financial, and operational outcomes. By providing a comprehensive data and analytics platform, ignite, and various applications built on top of it, the company enables clients to integrate and analyze data from disparate sources, identify areas for improvement, and implement data-driven solutions. The companys expertise extends to providing professional services, including data governance, data modeling, quality and process improvement, and population health strategies.

The companys diverse clientele includes academic medical centers, integrated delivery networks, community hospitals, and other risk-bearing entities, indicating a broad market presence. As a health care technology firm, HCAT is positioned to capitalize on the growing demand for data-driven healthcare solutions, driven by the need for improved patient outcomes, reduced costs, and increased operational efficiency.

Analyzing the , HCATs current price is $4.13, with a 20-day SMA of $3.95, indicating a recent uptrend. The stock is currently below its 50-day SMA ($4.17) and significantly below its 200-day SMA ($6.48), suggesting a longer-term downtrend. The ATR of $0.32 represents a 7.81% daily volatility, which is relatively high. The stock is trading near the lower end of its 52-week range ($3.58 - $9.02), potentially indicating underselling or undervaluation.

From a fundamental perspective, the reveals a market capitalization of $287.40M and a forward P/E of 19.69, suggesting that investors are willing to pay a premium for the companys expected future earnings growth. However, the lack of a current P/E ratio and a negative RoE (-19.30%) indicate that the company is currently unprofitable.

Forecasting future performance based on both and , a potential scenario could unfold as follows: if HCAT continues to execute on its growth strategy, expanding its data and analytics capabilities and increasing its market share, it may eventually achieve profitability, potentially driving the stock price upwards. A break above the 50-day SMA ($4.17) and sustained trading above it could be an initial bullish signal. A further move towards the 200-day SMA ($6.48) would indicate a significant trend reversal. However, failure to achieve profitability or missing growth expectations could result in continued downward pressure on the stock price.